get commercialization competitiveness, to for I LEQEMBI. to like interesting I just start details think moment. of everybody. with and you, Thank morning, the Chuck. a before really we all Good And like pause into I'd off
have the dozens treatment historic an history. And and talking literally first moment of full there ever have that full from very before market. has received the got disease-modifying this been is failed drug approved been -- in approval medicines to FDA We're that's reimbursement from This about CMS. healthcare
is for still that important that's first we an reasons, is the know. there And awful a lot couple of don't
to physicians at patients are to to disease really we really proposing the much prescribing of the very big like able going can and But And also awful have perhaps going are been an practice We medicine. of or the understand Physicians a on affect a is really these treat this to how help really products it's and patients. that of beyond how practice impact haven't change here lot Alzheimer's beginning that. disease. treatment Donepezil we journey
about So that how not things, we ADUHELM get really to marketplace as intent and actually know physicians never at until got are got we know, you But as never it thinking approved. start patients all out there of going really on and did the get to and see out how actually blocks, we're respond. prescribe looking launched. the
is not this whenever an first. and that this discovering first, be of predictable. going you're So lot a a lot you're is really awful just And
a Within out Korea. South of Britain, again the to able get short Great very our time, China, the Japan, to in Eisai. would, and filings colleagues just call were kudos at they EU, I Canada, to, period regulatory
this to a going launch. So truly is global be
and last a going -- we months looking week, the to will that. are actually looked really this we're have years. But one has Donanemab the next when had is I start this become over more a about whole bit plaques, to looking moving is we've think and at, at most just story, people we are Most little very A-beta an okay, these there's have and different got that. off more don't products. AAIC people antibody and Now, at but Lecanemab, evolve lot the and of Priya And obvious two cover things
This in -- safety because mechanisms design been been have a populations. they is profile. very different have of And studied have They've are different binding. design studied these approaches. they They've study different different They different process clinical course a products. in -- different -- with
to interesting all interesting And these out see the and And play is, years. months to that would there data, how this of the lot this, of into just to subtlety and be get the commercial I we coming all of it's point in over it'll view. differences of caution are an going and awful quite be marketplace to as but you from is everybody, a going see
and diagnostics. to get treatment going will reimbursement. companies going We're getting It's an We to to full be how is did month underway occur, approval unusual to research is lot is This to There's has be patient the blood going also, launch an to that have also for a to you other launch. this approval and know, CMS that investing process lot help others. earlier in in the navigate of The awful US. encourage the significance understand be done. as navigators has
of An to working will awful physician We with occur change in have be the will lot offices. practice.
There's education around New and practices awful sure lot in on place. are safety making a right patients of an day-to-day that basis. the
reached centers have to date. out about We to XXX
CMS. beyond We're also getting reimbursement
commercial far, had the We insurers. so example, a from of have in very for Medicaid, good we response XX states and -- XX have out
So, LEQEMBI course, we as to the of further get the launch you to start keep very off a date is good patients. I we'll, of up think and
another on to move Now, here. slide
at as for we where been lot past doing we that growth. One is things sure looked we've months the of in there's were. are really company, making that an the And the awful we well-positioned
product know, As investment profile, product of a have would the Generally, expect mature level today, when mature you profile. go a relatively you to down. we you have
of also legacy relatively extremely we versus is we got we levels. high But actually an organizational over-investment governance. Part We've an But when in that have operating benchmark other products. have companies. centralized expenses many
have span we On of have of average, control control. three. a We a of span low
five in were up XX R&D of products high-cost result, I of highest we we've that's different that years, high-risk R&D as the necessarily and value. not and heads relatively a And some and And organization. R&D for then think with an look at pipeline, not good we had the as ended
been to project value-based an we at where R&D entirely. to Biogen share well, market for extensive existing in And looked really We multiple decisions be still we've want we do promotional those we review want through has more the be, XX% programs. sclerosis. as don't remove So to making effort products. to just want
share We a highest considerable have the market margin. by
there depend -- there is products. who lot patients Biogen of so on And an are awful
smarter. think that can I do we
in need high-value decision-making It's cost, launches. There if optimized, focus these greater value, is strong our in want but We important to a we manage projects the on shareholder we R&D. clearly a can product to obviously to customers, agility need make to new the closer we get want of investment in organization, launches. to success have most and really
External growth will give diversify opportunity rare away -- really immunology, diseases to and us from neuropsychiatry. rare into the diseases, diversify
this What look where bottom-up products. you was be did exercise new do company successfully a effort. we we did at to we know launched So redesign to as need a
opportunities mechanisms that say, Biogen What of accountability? lead been, do which year. least to we governance Of $XXX kind There want? will forward. internal a growth invest savings. $X so of that, cost per I'd want? about and cost-savings metrics at be kind savings And there's of are some we in billion going What kind billion gross redesign What annualized do expect to will in complete we of
for an fit launches, opportunity year, growth. this that truly in before is sure into the So make we really were product to this we get
that, with over And Priya. I turn will it to
